| | Why Do Biotech Companies Choose New Jersey?
New Jersey has a flourishing ecosystem that includes partnering opportunities with leading companies and research universities; more than 8.3 million square feet of lab and incubator space; and attractive incentives and VC funding for biotech companies at every stage of their growth.
Visit the New Jersey Pavilion, Booth #1737 and learn more about the benefits of a New Jersey location, including access to a talent pool with deep experience in discovery and commercialization.
You're Invited to our 7th Annual Choose New Jersey Reception
Join New Jersey's top life science executives for conversation and cocktails to kick off BIO 2017.
When: Monday, June 19 from 5:00-7:00 pm
Where: Top of the Hyatt at the Grand Hyatt San Diego (adjacent to the Convention Center) RSVP here to reserve your spot. |
| | Your proven partner for manufacturing of drug substances and sterile injectable drug products
Emergent BioSolutions is dedicated to one simple mission - to protect and enhance life.
Our Contract Development and Manufacturing capabilities support bulk drug substances and sterile injectable drug products from Phase I through commercial scale production. Incorporating research, full product/process development and non-clinical/clinical staffing, our highly-experienced team is responsible for developing and/or commercializing innovative therapeutic products and technologies that protect and enhance life. Our manufacturing facilities (located in Baltimore, MD) currently produce 20 commercial products approved for distribution in over 50 countries, and since 1998 have supported over 200 clinical stage programs from Phase 1 through Phase 3, making Emergent a proven partner.
See how Emergent BioSolutions can enhance your business. |
| | BioVectra Inc. to Open New Microbial Fermentation and Complex Chemistry Site in December 2017
BioVectra is opening a fourth cGMP facility with 40,000 liters (L) of fermentation capacity, state-of-the-art downstream processing equipment, potent handling capabilities and development suites for fermentation and chemistry processes. The facility will be operational by December 2017, increasing BioVectra's total manufacturing capacity by more than 40%.
This $30M expansion is a continued enrichment of BioVectra's core development and manufacturing competencies: microbial fermentation and complex chemistries As an industry leader in large-scale microbial fermentation of both small and large molecules, BioVectra provides scalable cGMP operations from 30 L to 17,000 L. The new facility is located in Windsor, Nova Scotia, with proximity to Northeast US development entities.
Connect with us at the BIO International Convention (Booth #1450) to learn more! |
|
